A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase
- PMID: 16546972
- DOI: 10.1158/1535-7163.MCT-05-0384
A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase
Abstract
Ribonucleotide reductase plays a central role in cell proliferation by supplying deoxyribonucleotide precursors for DNA synthesis and repair. The holoenzyme is a protein tetramer that features two large (hRRM1) and two small (hRRM2 or p53R2) subunits. The small subunit contains a di-iron cluster/tyrosyl radical cofactor that is essential for enzyme activity. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP) is a new, potent ribonucleotide reductase inhibitor currently in phase II clinical trials for cancer chemotherapy. Ferric chloride readily reacts with Triapine to form an Fe(III)-(3-AP) complex, which is reduced to Fe(II)-(3-AP) by DTT. Spin-trapping experiments with 5,5-dimethyl-1-pyrroline-N-oxide prove that Fe(II)-(3-AP) reduces O2 to give oxygen reactive species (ROS). In vitro activity assays show that Fe(II)-(3-AP) is a much more potent inhibitor of hRRM2/hRRM1 and p53R2/hRRM1 than Triapine. Electron paramagnetic resonance measurements on frozen solutions of hRRM2 and p53R2 show that their tyrosyl radicals are completely quenched by incubation with Fe(II)-(3-AP). However, the enzyme activity is maintained in protein samples supplemented with catalase alone or in combination with superoxide dismutase. Furthermore, catalase alone or in combination with superoxide dismutase markedly decreases the antiproliferative effect of Triapine in cytotoxicity assays. These results indicate that Triapine-induced inhibition of ribonucleotide reductase is caused by ROS. We suggest that ROS may ultimately be responsible for the pharmacologic effects of Triapine in vivo.
Similar articles
-
Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study.J Inorg Biochem. 2011 Nov;105(11):1422-31. doi: 10.1016/j.jinorgbio.2011.07.003. Epub 2011 Jul 31. J Inorg Biochem. 2011. PMID: 21955844 Free PMC article.
-
Mechanistic studies of semicarbazone triapine targeting human ribonucleotide reductase in vitro and in mammalian cells: tyrosyl radical quenching not involving reactive oxygen species.J Biol Chem. 2012 Oct 12;287(42):35768-35778. doi: 10.1074/jbc.M112.396911. Epub 2012 Aug 22. J Biol Chem. 2012. PMID: 22915594 Free PMC article.
-
Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits.Biochem Biophys Res Commun. 2006 Feb 10;340(2):428-34. doi: 10.1016/j.bbrc.2005.12.019. Epub 2005 Dec 15. Biochem Biophys Res Commun. 2006. PMID: 16376858
-
Neuroprotective activity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811), a cancer therapeutic agent.CNS Drug Rev. 2006 Spring;12(1):77-90. doi: 10.1111/j.1527-3458.2006.00077.x. CNS Drug Rev. 2006. PMID: 16834759 Free PMC article. Review.
-
Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.Curr Med Chem. 2001 Feb;8(2):121-33. doi: 10.2174/0929867013373741. Curr Med Chem. 2001. PMID: 11172670 Review.
Cited by
-
Anticancer activity of metal complexes: involvement of redox processes.Antioxid Redox Signal. 2011 Aug 15;15(4):1085-127. doi: 10.1089/ars.2010.3663. Epub 2011 May 11. Antioxid Redox Signal. 2011. PMID: 21275772 Free PMC article. Review.
-
Estrone-salicylaldehyde N-methylated thiosemicarbazone hybrids and their copper complexes: solution structure, stability and anticancer activity in tumour spheroids.J Biol Inorg Chem. 2021 Oct;26(7):775-791. doi: 10.1007/s00775-021-01891-7. Epub 2021 Aug 28. J Biol Inorg Chem. 2021. PMID: 34453218
-
Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer.Drug Discov Today. 2015 Nov;20(11):1391-7. doi: 10.1016/j.drudis.2015.07.006. Epub 2015 Jul 20. Drug Discov Today. 2015. PMID: 26205328 Free PMC article. Review.
-
In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer.Sci Rep. 2021 Apr 13;11(1):8042. doi: 10.1038/s41598-021-87325-5. Sci Rep. 2021. PMID: 33850183 Free PMC article.
-
Desulfurization of thiosemicarbazones: the role of metal ions and biological implications.J Biol Inorg Chem. 2024 Feb;29(1):3-31. doi: 10.1007/s00775-023-02037-7. Epub 2023 Dec 26. J Biol Inorg Chem. 2024. PMID: 38148423 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources